07:00 , Jun 13, 2011 |  BioCentury  |  Emerging Company Profile

Cyterix: CYPing on prodrugs

Current prodrug technologies for cancer either cannot discriminate between healthy and tumor cells, and thus become active in both cell types, or are activated only in specific cells within solid tumors. Cyterix Pharmaceuticals Inc. believes...
07:00 , Apr 22, 2002 |  BC Week In Review  |  Clinical News

ZYC300: Zycos started a U.S. Phase I/II of ZYC300 trial in patients with breast, ovarian, colorectal or prostate cancer

Zycos Inc. , Lexington, Mass.   Product: ZYC300   Business: Cancer   Therapeutic category: Immune modulation   Target: Cytochrome P450 1B1 (CYP1B1)   Description: DNA vector that induces specific T cell responses against CYP1B1 expressing...
08:00 , Jan 28, 2002 |  BioCentury  |  Finance

Ebb & Flow

ImClone's fall appeared to hit a sordid bottom on Thursday with a "tell-all" story in The New York Times that ventured into the personal lives of the company's management. But IMCL filed several 8-Ks on...
07:00 , Jul 16, 2001 |  BC Week In Review  |  Clinical News

CYP1B1 regulatory update

Zycos received U.S. Patent No. 6,242,203 covering use of polyclonal or monoclonal CYP1B1 antibodies to detect cancer cells in tissue samples or human cells. Zycos Inc. , Lexington, Mass.   Product: CYP1B1 ( cytochrome P450...
07:00 , Oct 2, 2000 |  BC Week In Review  |  Company News

Zycos, University of Massachusetts Medical School deal

Zycos received exclusive worldwide rights from the university to therapeutic and diagnostic applications of the CYP1B1 tumor-specific cytochrome P450 protein in specific fields. The university will receive license fees and is eligible for milestones and...
07:00 , Aug 3, 1998 |  BC Week In Review  |  Clinical News

InSite regulatory update

ISV received notice of allowance for a U.S. patent covering methods for the diagnosis of primary congenital glaucoma using the CYP1B1 gene. InSite Vision Inc. (ISV), Alameda, Calif.   Business: Ophthalmic  ...
07:00 , Aug 18, 1997 |  BC Week In Review  |  Company News

InSite, University of Connecticut Health Center deal

INSV acquired an exclusive worldwide license from the university to diagnostic uses of the Cytochrome P450 1B1 (CYP1B1) gene implicated in primary congenital glaucoma. The gene is associated with 85 percent of cases of the...
08:00 , Mar 24, 1997 |  BC Week In Review  |  Company News

InSite other research news

Researchers at the University of Connecticut Health Center (Farmington, Conn.) have identified a major gene associated with primary congenital glaucoma, an autosomal recessive disorder that affects children from birth to three years. The condition, believed...